Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K
Cancer Vaccines01:30

Cancer Vaccines

1.4K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.4K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

8.5K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
8.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combinatorial delivery of low-dose radiotherapy and immunotherapy to patients with immune-excluded tumors enhances CD8+ T cell functionality.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Cancer immunotherapy insights: key takeaways from the ADSCC bone marrow and cellular therapy congress 2024.

Frontiers in immunology·2026
Same author

Highly efficient gene knockout in tumor-infiltrating lymphocytes by adenine base editing.

Molecular therapy. Oncology·2025
Same author

The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee.

Journal for immunotherapy of cancer·2025
Same author

Multi-modal image analysis for large-scale cancer tissue studies within IMMUcan.

Cell reports methods·2025
Same author

Immune correlates and mechanisms of TIL therapy efficacy: current insights and knowledge gaps.

Trends in cancer·2025

Related Experiment Video

Updated: Apr 19, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

2.0K

Potential approaches for more successful dendritic cell-based immunotherapy.

Cheryl Lai-Lai Chiang1, Klara Balint, George Coukos

  • 1University of Pennsylvania Medical Center, Ovarian Cancer Research Center , Philadelphia, PA 19104 , USA Lana.Kandalaft@chuv.ch ; cheryl_chiang@yahoo.com.

Expert Opinion on Biological Therapy
|January 3, 2015
PubMed
Summary

Dendritic cell (DC) vaccines enhance antitumor T-cell responses by optimizing DC subsets, manufacturing, antigens, and adjuvants. Combining DC immunotherapy with Treg depletion or VEGF blockage can improve long-term cancer remission.

Keywords:
cancerdendritic cellimmunotherapyvaccines

More Related Videos

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.8K
Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo
10:35

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

4.1K

Related Experiment Videos

Last Updated: Apr 19, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

2.0K
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.8K
Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo
10:35

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

4.1K

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Dendritic cells (DCs) are crucial for initiating antitumor T-cell responses.
  • Targeting DCs offers a promising strategy for cancer immunotherapy.

Purpose of the Study:

  • To review critical factors for enhancing dendritic cell (DC) vaccine efficacy.
  • To explore combinatorial strategies with immunomodulatory therapies for improved antitumor immunity.

Main Methods:

  • Discussion of optimal DC subsets, manufacturing protocols, antigen loading, and adjuvant selection.
  • Analysis of combination strategies including T-regulatory cell depletion, VEGF blockade, and checkpoint inhibition.

Main Results:

  • Monocyte-derived DCs are clinically prevalent; Langerhans cells and plasmacytoid DCs show high efficacy in cytotoxic T lymphocyte induction.
  • Optimizing DC manufacturing and antigen loading is key for generating potent vaccines.

Conclusions:

  • Future DC-based immunotherapy aims to combine DCs with immunomodulatory agents for optimal antitumor responses.
  • Combination therapies hold potential for achieving long-term cancer remission or cure.